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Abstract
The retinal degenerations (RDs) are a family of inherited retinal degenerative diseases (dystrophies) that lead to vision loss.
Although phenotypically very diﬀerent, the RDs have several characteristics in common. They all are caused by gene mutations or at
least have a genetic component in the etiology. They all lead to photoreceptor dysfunction, many leading to the death of both rod
and cone photoreceptors. The mechanism of cell death in most of the RDs seems to be through the process of apoptosis. It is
estimated that more than ﬁfteen million people around the world have vision loss due to an inherited RD. Many of these are patients
with the dry form of age-related macular degeneration (AMD) who retain partial functional vision. However, some have other
degenerative conditions such as retinitis pigmentosa, Leber congenital amaurosis or wet AMD and can suﬀer from severe vision loss
or total blindness.  2002 Published by Elsevier Science Ltd.
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1. Natural animal models
The good news for RD patients is that there are a
number of natural animal models available for studying
these diseases. Importantly, many of the genes found to
be mutated in animals that result in a retinal degenera-
tion (RD) have been found to be similarly abnormal in
the human. Thus, in many ways, these animal models are
true ‘‘models’’ in that they faithfully mimic the human
disease genetically and also produce similar phenotypic
conditions of vision loss. The importance of these models
lies in several diﬀerent areas. First, the animal models
have given us a rich supply of candidate genes for testing
in the human. Finding the animal gene mutation can be a
long and arduous task but, once done, the gene can be
quickly tested in the human, usually with rapid, positive
results. Second, one can study the pathology and cell
biology of the mutated gene and its gene product. Un-
derstanding, e.g., how a mutated protein of diminished
or destroyed function subserves a particular cellular
function could lead to development of a drug or natural
substance to partially or even fully alleviate the block.
Third, another important use, obviously, is in testing
treatment regimens for eﬃcacy and for safety. Demon-
strating ‘‘proof of principle’’ in one or more animal
models for presentation to the FDA can go far in moving
a therapy towards human clinical trials. Similarly, dem-
onstrating safety in one (preferably two or three) animal
species allows for greater comfort in approaching human
experiments and trials.
The natural animal models come in many forms,
sizes, phyla and ﬂavors––some even tasting like chicken.
Low in phylogenetic classiﬁcation but not in usefulness
is the fruitﬂy (Drosophila melanogaster). This model has
certainly been important in understanding normal
pathways in the visual process. Moreover, with the large
number of mutants available, the ability to breed up
large numbers of animals and their short life cycle, the
fruitﬂy has been a key animal model in pinpointing
mutated genes that can lead to RD (Pak, 1995). At the
vertebrate level, the zebraﬁsh has many of the same
characteristics, with large-scale screening able to be ac-
complished in a relatively quick and inexpensive manner
(Brockerhoﬀ et al., 1995). The chicken has the advan-
tage of having a relatively large proportion of cone
photoreceptor cells, somewhat similar to that of the
human retina (Semple-Rowland & Lee, 2000).
RDs in mammals have long been recognized, the ar-
chetypes being the rodlessmouse (Keeler, 1924), the RCS
rat (Bourne, Campbell, & Tansley, 1938; Dowling &
Sidman, 1962), and the retinal degeneration slow (rds)
mouse models (Van Nie, Ivanyi, & Demant, 1978). The
rodless mouse was the ﬁrst mammalian RD described
(1920s), and was later shown to be identical to the rd
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mouse, a now widely researched model of recessive RD
(Pittler, Keeler, Sidman, & Baehr, 1993). The rds model
was described in the late 70s and extensively character-
ized in the 80s by Prof. Somes Sanyal (Sanyal & Jansen,
1981). Larger animal models are also useful for all the
reasons given above but are particularly important in
establishing eﬃcacy and safety parameters prior to
human treatments. Several canine models of inherited
RD have been identiﬁed, and in some cases, colonies of
aﬀected animals have been established. Aguirre and co-
workers have identiﬁed and characterized several forms
of canine RD with almost a dozen diﬀerent models now
available. These are mostly autosomal recessive condi-
tions although an X-linked model is being characterized.
The defect in the Irish Setter is particularly interesting
since it exhibits the same defect in the cyclic GMP
phosphodiesterase b-subunit gene observed in the rd
mouse and in some human families with recessive reti-
nitis pigmentosa (RP) (Aguirre, 1978; Suber et al., 1993).
This gives the opportunity of studying faithful models of
human RP disease both in small (mouse) and larger (dog)
animals. Cat models of inherited RD have also been
described. Autosomal recessive progressive retinal atro-
phy (PRA) in the Abyssinian cat has been particu-
larly well characterized (Narfstrom, 1983). An autosomal
dominant form of PRA has also been reported in this
animal (Barnett & Curtis, 1985). Gene mutations in these
feline models have yet to be elucidated.
2. Genetically engineered animal models
The not-so-good news for work on RDs is that the
repertoire of natural models is limited. Most of the
natural animal models are for recessive forms of RP, a
good natural model for dominant RP, e.g., has yet to be
found. Similarly, there is yet no exact model for dry age-
related mascular degeneration (AMD) or for the cho-
roidal vascularization found in wet AMD. The ‘‘exact’’
animal of choice for AMD, of course, would have to be
a primate since only they have a macula as in the
human. Finally, there are no exact models for many of
the rare forms of RD, notably the forms of Usher syn-
drome. However, great progress has been made over the
last few years in constructing bioengineered animal
models that mimic the human diseases. Through trans-
genic animals, knockouts, etc., ‘‘new’’ models can be
generated. To date, rodent and pig models have been
engineered, notably, some expressing dominant forms of
RD.
Many examples are now in the RD literature where
transgenic mice have been produced bearing a mutated
gene that leads to phenotypic RD. For example, Naash
et al. introduced a mutated opsin gene into the mouse,
producing a good simulation of the course of human
autosomal dominant RP (Naash, Hollyﬁeld, Al-Ubaidi,
& Baehr, 1993). More recently, Hong et al. produced a
murine model for X-linked retinitis pigmentosa (RP3)
(Hong et al., 2000). Through gene knockout techniques,
they created an RPGR-deﬁcient model that resulted in
both rod and cone cell degeneration. In these mutants,
the pathobiology of the disease process can be eluci-
dated. In this case, the RPGR mutation leads to a dis-
ruption of the unidirectional movement of opsin in the
photoreceptor cell with resultant cell degeneration. Ge-
netic engineering in a larger animal model has produced
an excellent model for RP in the pig. The pig eye is not
only similar in size to the human but has a fairly similar
number and distribution of rod and cone cells. In a
heroic undertaking, Petters et al. have produced a por-
cine model in which the degeneration is quite similar to
human RP (Petters et al., 1997). The transgenic animals
expressing a mutated opsin gene (Pro347Leu) have early
rod loss with slower cone cell degeneration, making the
pig a very attractive model for preclinical eﬃcacy and
safety trials.
Finally, progress is being made in developing models
for general macular degeneration and AMD. For Star-
gardt disease and perhaps dry AMD, an ABCR
(ABCA4) knock-out mouse was developed by Travis
and coworkers (Weng et al., 1999) that simulates the
human disease process in many aspects. For wet AMD,
no model is yet fully representative of the macular
and choroidal neovascularization seen in the human
although some transgenic animals are available for
studying intraretinal and subretinal new vessel growth in
the mouse, e.g. (Okamoto et al., 1997).
3. Animal model uses: candidate genes and pathobiology
Rapid screening of visual mutants in Drosophila and
examination of genes important to normal Drosophila
visual function has been useful in pinpointing genes
causing RD in the human. Mutations in the human
homolog of the Drosophila crumbs gene, e.g., has been
found to cause pigment epithelial cell abnormalities and
RD in patients of the RP12 phenotype (den Hollander
et al., 1999). Important work on the rd chicken has lead
to the identiﬁcation of a null mutation in the photore-
ceptor-speciﬁc guanylate cyclase gene that causes a RD
analogous to the human condition of Leber’s congenital
amaurosis (LCA) (Semple-Rowland, Lee, Van Hooser,
Palczewski, & Baehr, 1998).
As with the chicken, much work over many years has
ﬁnally led to elucidation of the gene (MERTK) causing
the phagocytosis problem and ensuing RD in the RCS
rat (D’Cruz et al., 2000). Rapidly thereafter, mutations
in the human ortholog to this gene were found to cause
RP (Gal et al., 2000). In the rds mouse, Travis and co-
workers cloned the gene in the late 80s and soon iden-
tiﬁed the gene product as a structural protein restricted
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to and stabilizing photoreceptor outer segment discs
(Travis, Brennan, Danielson, Kozak, & Sutcliﬀe, 1989;
Travis, Sutcliﬀe, & Bok, 1991). Because of its impor-
tance in photoreceptor cell biology in maintaining outer
segment integrity, mutations in peripherin/rds are now
known to be involved in over 40 types of human RDs,
e.g. (Keen & Inglehearn, 1996). These range from types
of RP to progressive macular degenerations (Wells et al.,
1993). This is a prime example of the ‘‘ripple eﬀect’’
where genetic analysis of a single animal model can lead
to wide ranging advances in understanding several
forms of human RD disease.
An excellent example of the usefulness of animal
models in the convergence of normal cell biology and
pathobiology studies on the photoreceptor neuron is
seen in work on the ABCA4 gene. It is now clear that the
well known rim protein (RmP) is identical to the more
recently characterized ABCA4 gene product whose
mutation(s) cause Stargardt disease (Azarian & Travis,
1997). In the ABCA4 knockout mouse (Weng et al.,
1999), both electrophysiological and morphological
signs of RD are produced. In particular, deposition of
the lipofuscin ﬂuorophore A2E is seen in the RPE layer,
possibly resulting in ‘‘poisoning’’ of the RPE cells and
secondary loss of photoreceptor cells. Recent work with
the abcr= mutant clearly demonstrates inhibition of
A2E formation in mice raised in darkness, implicating
light as a factor in at least some RDs (Mata, Weng, &
Travis, 2000). Evidence from cell biological studies in-
dicates that the ABCA4 protein is a fairly speciﬁc target
for photooxidative damage in the photoreceptor neuron
and that individuals with ‘‘diminished ABCR activity’’
may be at particular risk to photodamage (Sun &
Nathans, 2001).
Finally, animal work has been generally helpful in
clarifying the question of light damage to photorecep-
tors and in producing a ‘‘light-damage model’’ for
simulation of RD which can be used to test possible
therapies. Light damage and ensuing photoreceptor cell
death have been known for several decades now (Noell,
Walker, Kang, & Berman, 1966). The biological mech-
anism of such damage, however, is only recently being
unraveled. It is now known that the apoptotic cell death
induced by light damage is dependant on the presence of
functional rhodopsin in the photoreceptor. Studies on
tansgenic mice expressing mutant forms of rhodopsin
suggested a link between light damage and the presence
of active rhodopsin (Naash et al., 1996). More recently,
Grimm et al. have used RPE65-deﬁcient mice to dem-
onstrate the central role of rhodopsin in generation or
transduction of the ‘‘death signal’’ and that the tran-
scriptional factor AP-1 is a key element in light-induced
cell death (Grimm et al., 2000). Induction of the speciﬁc
heat shock protein HO-1 had previously given strong
evidence that light ‘‘insult’’ resulted in oxidative damage
to the retina (Kutty et al., 1995) as had been postulated
by Organisciak and coworkers (Organisciak, Darrow,
Jiang, Marak, & Blanks, 1992).
4. Animal model uses: preclinical testing
Having an adequate animal model(s) is of almost
overriding importance in preclinical testing of any po-
tential treatment. Small inexpensive animal models can
be very useful in the earlier phases of investigation
where larger numbers of subjects are generally needed.
Larger-sized animal models can then be used to ﬁne tune
the results and better address the questions of safety,
dose, delivery, etc. Certainly, the FDA wants to see
adequate evidence for eﬃcacy and for safety prior to
approval of human clinical trials. Also, establishing
these parameters is often helpful in persuading a biotech
or pharmaceutical company to move to the human tri-
als. So far, scientiﬁc ‘‘proof of principle’’ has been es-
tablished in a number of animal models for at least
partial eﬃcacy in the areas of transplantation, pharma-
ceutical therapy and gene therapy.
One of the early positive uses of animal models in
exploring therapies for RD was in the transplantation
study by Turner and coworkers (Li & Turner, 1988). In
this study and many thereafter from several laborato-
ries, the eﬃcacy and relative safety of RPE cell trans-
plants was demonstrated in the RCS rat model. Proof of
eﬃcacy for photoreceptor transplantation has been
more elusive although light-driven ganglion cell re-
sponses have been reported in rd mice after transplan-
tation of young (13 day) host retina (Radner et al.,
2001). More recently, transplantation studies have been
expanded to examine the possible use of stem (proge-
nitor) cells in photoreceptor replacement. Young and
coworkers, e.g., have demonstrated a level of neuronal
diﬀerentiation and morphological integration of hippo-
campal progenitor cells transplanted into the retina of
the RCS rat (Young, Ray, Whiteley, Klassen, & Gage,
2000). Interestingly, a positive eﬀect on cone survival in
the RD mouse was reported recently employing selective
transplantation of rod photoreceptor cells, opening
up questions of rod–cone interaction and survival fac-
tor production, among others (Mohand-Said, Hicks,
Dreyfus, & Sahel, 2000). An excellent review of the
transplant ﬁeld and the use of animal models has been
recently published (Lund et al., 2001).
Another important use of animal models is in the
area of pharmaceutical therapy––i.e., the study of drugs,
growth factors and natural substances that function as
neuron-survival agents to slow down or even halt the
progression of the retinal degenerative disease process.
The seminal work of LaVail, Steinberg and coworkers
ﬁrst demonstrated the eﬃcacy of one of the neuron-
survival agents, bFGF, in slowing the progression of the
RD of the RCS rat (Faktorovich, Steinberg, Yasumura,
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Matthes, & LaVail, 1990). Since then, numerous animal
models have been used to demonstrate the neuronal
protective eﬀect of several diﬀerent agents on the dys-
trophic retina (LaVail et al., 1998). This ‘‘proof of
principle’’ along with the relative safety of most of the
agents tested in the animal models indicates the feasi-
bility of human clinical trials at some point in the future.
Other potentially neuroprotective agents have been
tested in animal models, some with positive results. The
use of orally administered retinoids has been found to
result in ‘‘dramatic improvement in rod physiology’’ in
RPE65-deﬁcient mice, ostensibly allowing for bypass of
the block in the visual cycle caused by the mutation (Van
Hooser et al., 2000). Somewhat similarly, vitamin A
supplementation ‘‘signiﬁcantly reduced the decline of a-
wave and b-wave amplitudes’’ in the T17Mopsin mutant
mouse but did not do so in the P347S mutant (Li et al.,
1998). This is an important ﬁnding since it could lead the
way in deﬁning human genetic subsets that are or are not
amenable to a particular treatment. In the light-damage
rodent model, 13-cis retinoic acid (RA) was found to
protect photoreceptors from light-induced degeneration
(Sieving et al., 2001). Since administration of 13-cis RA
markedly slowed rhodopsin regeneration among other
eﬀects, it was suggested that ‘‘strategies of altering reti-
noid cycling may have therapeutic implications for some
forms of retinal and macular degeneration’’. Also in the
light-damage model, a variety of antioxidative agents
have been shown to be protective (Organisciak et al.,
1991; Kutty et al., 1995). Halothane (Keller, Grimm,
Wenzel, Hafezi, & Reme, 2001) and glucorticoid acti-
vation (Wenzel et al., 2001) appear to both be neuro-
protective in the rhodopsin-mediated, light-damage
model. These very positive results point out another need
in moving towards RD therapies––i.e., eﬀective means of
drug delivery to the retina. This area of investigation is
just beginning but, as the potential therapies multiply,
animal model experiments should lead the way in de-
termining the best method of getting eﬀective doses of
protective agents to the posterior segment of the eye.
The canine models can also be used eﬀectively for
studies on eﬃcacy and safety of treatment regimens––
not always with positive results. Miniature poodles with
progressive rod–cone degeneration (prcd) exhibit de-
creased levels of docosahexaenoic acid (DHA, 22:6n-3)
much as seen in some human patients with RP
and Usher syndrome. If this biochemical deﬁcit re-
sults from a primary genetic problem, it was reasoned
(Aguirre, Acland, Maude, & Anderson, 1997) that DHA
replacement therapy through the diet might slow or even
reverse the cause of the disease. Although DHA sup-
plementation was not found to alter the course of the
prcd phenotype, it did demonstrate the usefulness of the
model in eﬃcacy testing. Similar negative results have
been obtained when the use of a calcium channel blocker
was not found to slow the RD in the rcd1 canine model
of RD carrying a null mutation in the PDE6B gene
(Pearce-Kelling et al., 2001). These results are diﬀerent
from those in the rd mouse (with an identical gene de-
fect) where D-cis-diltiazem did provide partial protec-
tion to photoreceptors and visual function (Frasson
et al., 1999). Perhaps species speciﬁcities account for
these diﬀerences? In the dog, much more success has
been recently demonstrated in gene therapy eﬃcacy
trials in the Briard dog as described in the next section.
Proof of principle for gene therapy has now been well
established in both rodent and canine RD models.
Bennet and coworkers were the ﬁrst to deﬁnitively
demonstrate photoreceptor rescue by gene replacement
therapy in the rd mouse (Bennett et al., 1996). Subretinal
injection of Ad-CMV-bPDE elicited increased PDE
enzyme activity in the retina and delayed photoreceptor
death by several weeks. Recent work by Ali et al. not
only demonstrated partial restoration of outer segment
integrity in rds mice with a peripherin mutation but
functional restoration of an ERG signal as well (Ali
et al., 2000). Besides autosomal recessive disease models,
autosomal dominant models can be bioengineered and
used for eﬃcacy trials using ribozyme gene therapy.
Lewin and coworkers have done just that and success-
fully showed photoreceptor rescue in a transgenic rat
model of ADRP carrying a rhodopsin (P23H) mutation
(Lewin et al., 1998). In the same rat model, the eﬃcacy
of such treatment was recently shown even if applied
after signiﬁcant photoreceptor loss (LaVail et al., 2000).
Moreover, the long-term (>8 months) eﬃcacy of the
treatment was demonstrated. Thus, both recessive and
dominant forms of RP can be addressed by simple gene
replacement therapy or knock-down strategies, respec-
tively, with satisfactory eﬃcacy and safety. It is impor-
tant to note, however, that Dudus et al. have reported
signiﬁcant levels of the reporter protein, green ﬂuores-
cent protein (GFP), in the optic nerves and brains of
mice and dogs following intravitreal injection of rAAV-
GFP (Dudus et al., 1999). This ﬁnding certainly neces-
sitates follow-up work prior to human clinical trials.
Techniques of pharmaceutical therapy and gene
therapy can be eﬀectively combined to deliver a number
of neuroprotective agents to the retina (CNTF, BDNF,
etc.) as well as genes and their products that are known
to be neuroprotective (e.g., bcl-2). Abitbol and co-
workers, e.g., have shown delayed photoreceptor cell
degeneration after injection of a bFGF2 construct into
the eye of the 3 week old RCS rat (Neuner-Jehle et al.,
2000). Similarly, bcl-2 overexpression in transgenic
mouse models of RP (opsin and PDE mutants) as well
as in a light-damage model resulted in decreased pho-
toreceptor degeneration (Chen et al., 1996). A protective
eﬀect of bcl-2 gene therapy was also seen in the rds
mouse model (Nir, Kedzierski, Chen, & Travis, 2000).
Finally, recent gene therapy work in a larger animal
model is perhaps the best example of the possibility of
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not only sight preservation but sight restoration (Acland
et al., 2001). The Briard dog exhibits a congenital, severe
loss in vision similar to human children with LCA. Af-
fected animals within this breed are RPE65=, leading
to the vision defect. Using an AAV-RPE65, very suc-
cessful restoration of visual function was demonstrated
not only with fairly robust ERG responses but positive
psychophysical responses to simple visual cues. Impor-
tantly, the eﬀect seems to be persistent and gives great
hope for successful human gene therapy, at least for this
particular inherited RD.
5. Conclusion
The search for natural animal models of RD has
been long but exceedingly successful. Modern tech-
niques of molecular biology have added signiﬁcantly to
the models available for study. However, signiﬁcant
gaps yet are present in our animal armamentarium.
For example, better models for AMD, dry and wet,
are needed. Recent activity in primate bioengineering,
though, may give us these models. The cell biology
and pathophysiology of the AMD degenerative process
can then be better studied and manipulated. Ulti-
mately, though, the most important aspect of animal
model research will be in their usefulness for demon-
stration of eﬃcacy and safety of the many treatment
regimens under study for all the inherited degenera-
tions. This exciting prospect now seems to be a close
reality in all the areas described above. If we can
‘‘treat’’ or ‘‘cure’’ these diseases in animals, why not
the human?
References
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S.,
Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y.,
Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
(2001). Gene therapy restores vision in a canine model of childhood
blindness. Nature Genetics, 28, 92–95.
Aguirre, G. (1978). Retinal degenerations in the dog I. Rod Dysplasia.
Experimental Eye Research, 26, 233–253.
Aguirre, G. D., Acland, G. M., Maude, M. B., & Anderson, R. E.
(1997). Diets enriched in docosahexaenoic acid fail to correct
progressive rod–cone degeneration (prcd) phenotype. Investigative
Ophthalmology and Visual Science, 38, 2387–2407.
Ali, R. R., Sarra, G. M., Stephens, C., Alwis, M., Bainbridge, J. W.,
Munro, P. M., Fauser, S., Reichel, M. B., Kinnon, C., Hunt, D.
M., Bhattacharya, S. S., & Thrasher, A. J. (2000). Restoration of
photoreceptor ultrastructure and function in retinal degeneration
slow mice by gene therapy [in process citation]. Nature Genetics, 25,
306–310.
Azarian, S. M., & Travis, G. H. (1997). The photoreceptor rim protein
is an ABC transporter encoded by the gene for recessive Stargardt’s
disease (ABCR). FEBS Letters, 409, 247–252.
Barnett, K. C., & Curtis, R. (1985). Autosomal dominant progressive
retinal atrophy in Abyssinian cats. Journal of Heredity, 76, 168–
170.
Bennett, J., Tanabe, T., Sun, D., Zeng, Y., Kjeldbye, H., Gouras, P., &
Maguire, A. M. (1996). Photoreceptor cell rescue in retinal
degeneration (rd) mice by in vivo gene therapy. Nature Medicine,
2, 649–654.
Bourne, M. C., Campbell, C. A., & Tansley, K. (1938). Hereditary
degeneration of rat retina. British Journal of Ophthalmology, 22,
613–623.
Brockerhoﬀ, S. E., Hurley, J. B., Janssen-Bienhold, U., Neuhauss,
S. C., Driever, W., & Dowling, J. E. (1995). A behavioral screen for
isolating zebraﬁsh mutants with visual system defects. Proceedings
of the National Academy of Sciences of the United States of
America, 92, 10545–10549.
Chen, J., Flannery, J. G., LaVail, M. M., Steinberg, R. H., Xu, J., &
Simon, M. I. (1996). bcl-2 overexpression reduces apoptotic
photoreceptor cell death in three diﬀerent retinal degenerations.
Proceedings of the National Academy of Sciences of the United
States of America, 93, 7042–7047.
D’Cruz, P. M., Yasumura, D., Weir, J., Matthes, M. T., Abderrahim,
H., LaVail, M. M., & Vollrath, D. (2000). Mutation of the receptor
tyrosine kinase gene mertk in the retinal dystrophic RCS rat [in
process citation]. Human Molecular Genetics, 9, 645–651.
den Hollander, A. I., ten Brink, J. B., de Kok, Y. J., Van Soest, S., Van
den Born, L. I., van Driel, M. A., van de Pol, D. J., Payne, A. M.,
Bhattacharya, S. S., Kellner, U., Hoyng, C. B., Westerveld, A.,
Brunner, H. G., Bleeker-Wagemakers, E. M., Deutman, A. F.,
Heckenlively, J. R., Cremers, F. P., & Bergen, A. A. (1999).
Mutations in a human homologue of Drosophila crumbs cause
retinitis pigmentosa (RP12). Nature Genetics, 23, 217–221.
Dowling, J. E., & Sidman, R. L. (1962). Inherited retinal dystrophy in
the rat. Journal of Cell Biology, 14, 73–109.
Dudus, L., Anand, V., Acland, G. M., Chen, S. J., Wilson, J. M.,
Fisher, K. J., Maguire, A. M., & Bennett, J. (1999). Persistent
transgene product in retina, optic nerve and brain after intraocular
injection of rAAV. Vision Research, 39, 2545–2553.
Faktorovich, E. G., Steinberg, R. H., Yasumura, D., Matthes, M. T.,
& LaVail, M. M. (1990). Photoreceptor degeneration in inherited
retinal dystrophy delayed by basic ﬁbroblast growth factor. Nature,
347, 83–86.
Frasson, M., Sahel, J. A., Fabre, M., Simonutti, M., Dreyfus, H., &
Picaud, S. (1999). Retinitis pigmentosa: rod photoreceptor rescue
by a calcium-channel blocker in the rd mouse. Nature Medicine, 5,
1183–1187.
Gal, A., Li, Y., Thompson, D. A., Weir, J., Orth, U., Jacobson, S. G.,
Apfelstedt-Sylla, E., & Vollrath, D. (2000). Mutations in MERTK,
the human orthologue of the RCS rat retinal dystrophy gene, cause
retinitis pigmentosa. Nature Genetics, 26, 270–271.
Grimm, C., Wenzel, A., Hafezi, F., Yu, S., Redmond, T. M., & Reme,
C. E. (2000). Protection of Rpe65-deﬁcient mice identiﬁes rhodop-
sin as a mediator of light-induced retinal degeneration. Nature
Genetics, 25, 63–66.
Hong, D. H., Pawlyk, B. S., Shang, J., Sandberg, M. A., Berson, E. L.,
& Li, T. (2000). A retinitis pigmentosa GTPase regulator (RPGR)-
deﬁcient mouse model for X-linked retinitis pigmentosa (RP3) [in
process citation]. Proceedings of the National Academy of Sciences
of the United States of America, 97, 3649–3654.
Keeler, C. E. (1924). The inheritance of a retinal abnormality in white
mice. Proceedings of the National Academy of Sciences of the United
States of America, 10, 329–333.
Keen, T. J., & Inglehearn, C. F. (1996). Mutations and polymorphisms
in the human peripherin-RDS gene and their involvement in
inherited retinal degeneration. Human Mutation, 8, 297–303.
Keller, C., Grimm, C., Wenzel, A., Hafezi, F., & Reme, C. (2001).
Protective eﬀect of halothane anesthesia on retinal light damage:
inhibition of metabolic rhodopsin regeneration. Investigative Oph-
thalmology and Visual Science, 42, 476–480.
Kutty, R. K., Kutty, G., Wiggert, B., Chader, G. J., Darrow, R. M., &
Organisciak, D. T. (1995). Induction of heme oxygenase 1 in the
G.J. Chader / Vision Research 42 (2002) 393–399 397
retina by intense visible light: suppression by the antioxidant
dimethylthiourea. Proceedings of the National Academy of Sciences
of the United States of America, 92, 1177–1181.
LaVail, M. M., Yasumura, D., Matthes, M. T., Drenser, K. A.,
Flannery, J. G., Lewin, A. S., & Hauswirth, W. W. (2000).
Ribozyme rescue of photoreceptor cells in P23H transgenic rats:
long-term survival and late-stage therapy. Proceedings of the
National Academy of Sciences of the United States of America,
97, 11488–11493.
LaVail, M. M., Yasumura, D., Matthes, M. T., Lau-Villacorta, C.,
Unoki, K., Sung, C. H., & Steinberg, R. H. (1998). Protection
of mouse photoreceptors by survival factors in retinal degenera-
tions. Investigative Ophthalmology and Visual Science, 39, 592–
602.
Lewin, A. S., Drenser, K. A., Hauswirth, W. W., Nishikawa, S.,
Yasumura, D., Flannery, J. G., & LaVail, M. M. (1998). Ribozyme
rescue of photoreceptor cells in a transgenic rat model of
autosomal dominant retinitis pigmentosa. Nature Medicine, 4,
967–971.
Li, L., & Turner, J. E. (1988). Inherited retinal dystrophy in the RCS
rat: prevention of photoreceptor degeneration by pigment epithelial
cell transplantation. Experimental Eye Research 47, 771–785.
Li, T., Sandberg, M. A., Pawlyk, B. S., Rosner, B., Hayes, K. C.,
Dryja, T. P., & Berson, E. L. (1998). Eﬀect of vitamin A
supplementation on rhodopsin mutants threonine-17––methionine
and proline-347––serine in transgenic mice and in cell cultures [in
process citation]. Proceedings of the National Academy of Sciences
of the United States of America, 95, 11933–11938.
Lund, R. D., Kwan, A. S., Keegan, D. J., Sauve, Y., Coﬀey, P. J., &
Lawrence, J. M. (2001). Cell transplantation as a treatment for
retinal disease. Progress in Retinal and Eye Research, 20, 415–449.
Mata, N. L., Weng, J., & Travis, G. H. (2000). Biosynthesis of a major
lipofuscin ﬂuorophore in mice and humans with ABCR-mediated
retinal and macular degeneration. Proceedings of the National
Academy of Sciences of the United States of America, 97, 7154–
7159.
Mohand-Said, S., Hicks, D., Dreyfus, H., & Sahel, J. A. (2000).
Selective transplantation of rods delays cone loss in a retinitis
pigmentosa model. Archives of Ophthalmology, 118, 807–811.
Naash, M. I., Hollyﬁeld, J. G., Al-Ubaidi, M. R., & Baehr, W. (1993).
Simulation of human autosomal dominant retinitis pigmentosa in
transgenic mice expressing a mutated murine opsin gene. Procee-
dings of the National Academy of Sciences of the United States of
America, 90, 5499–5504.
Naash, M. L., Peachey, N. S., Li, Z. Y., Gryczan, C. C., Goto, Y.,
Blanks, J., Milam, A. H., & Ripps, H. (1996). Light-induced
acceleration of photoreceptor degeneration in transgenic mice
expressing mutant rhodopsin. Investigative Ophthalmology and
Visual Science, 37, 775–782.
Narfstrom, K. (1983). Hereditary progressive retinal atrophy in the
Abyssinian cat. Journal of Heredity, 74, 273–276.
Neuner-Jehle, M., Berghe, L. V., Bonnel, S., Uteza, Y., Benmeziane,
F., Rouillot, J. S., Marchant, D., Kobetz, A., Duﬁer, J. L.,
Menasche, M., & Abitbol, M. (2000). Ocular cell transfection with
the human basic ﬁbroblast growth factor gene delays photorecep-
tor cell degeneration in RCS rats. Human Gene Therapy, 11, 1875–
1890.
Nir, I., Kedzierski, W., Chen, J., & Travis, G. H. (2000). Expression of
Bcl-2 protects against photoreceptor degeneration in retinal
degeneration slow (rds) mice. Journal of Neuroscience, 20, 2150–
2154.
Noell, W. K., Walker, V. S., Kang, B. S., & Berman, S. (1966). Retinal
damage by light in rats. Investigative Ophthalmology, 5, 450–473.
Okamoto, N., Tobe, T., Hackett, S. F., Ozaki, H., Vinores, M. A.,
LaRochelle, W., Zack, D. J., & Campochiaro, P. A. (1997).
Transgenic mice with increased expression of vascular endothelial
growth factor in the retina: a new model of intraretinal and
subretinal neovascularization. American Journal of Pathology, 151,
281–291.
Organisciak, D. T., Darrow, R. M., Bicknell, I. R., Jiang, Y.-L.,
Pickford, M., & Blanks, J. C. (1991). Protection against retinal
light damage by natural and synthetic antioxidants. In J. G.
Hollyﬁeld, R. E. Anderson, & M. M. LaVail (Eds.), Retinal degen-
erations (pp. 189–201). Boca Raton, FL: CRC Press.
Organisciak, D. T., Darrow, R. M., Jiang, Y. I., Marak, G. E., &
Blanks, J. C. (1992). Protection by dimethylthiourea against retinal
light damage in rats. Investigative Ophthalmology and Visual
Science, 33, 1599–1609.
Pak, W. L. (1995). Drosophila in vision research. The Friedenwald
Lecture. Investigative Ophthalmology and Visual Science, 36, 2340–
2357.
Pearce-Kelling, S. E., Aleman, T. S., Nickle, A., Laties, A. M.,
Aguirre, G. D., Jacobson, S. G., & Acland, G. M. (2001). Calcium
channel blocker D-cis-diltiazem does not slow retinal degeneration
in the PDE6B mutant rcd1 canine model of retinitis pigmentosa.
Molecular Vision, 7, 42–47.
Petters, R. M., Alexander, C. A., Wells, K. D., Collins, E. B., Sommer,
J. R., Blanton, M. R., Rojas, G., Hao, Y., Flowers, W. L., Banin,
E., Cideciyan, A. V., Jacobson, S. G., & Wong, F. (1997).
Genetically engineered large animal model for studying cone
photoreceptor survival and degeneration in retinitis pigmentosa.
Nature Biotechnology, 15, 965–970.
Pittler, S. J., Keeler, C. E., Sidman, R. L., & Baehr, W. (1993). PCR
analysis of DNA from 70-year-old sections of rodless retina
demonstrates identity with the mouse rd defect. Proceedings of the
National Academy of Sciences of the United States of America, 90,
9616–9619.
Radner, W., Sadda, S. R., Humayun, M. S., Suzuki, S., Melia, M.,
Weiland, J., & de Juan, E., Jr. (2001). Light-driven ganglion ell
responses in blind rd mice after neural retinal transplantation.
Investigative Ophthalmology and Visual Science, 42, 1057–1065.
Sanyal, S., & Jansen, H. G. (1981). Absence of receptor outer segments
in the retina of rds mutant mice. Neuroscience Letters, 21, 23–26.
Semple-Rowland, S. L., & Lee, N. R. (2000). Avian models of
inherited retinal disease. Methods in Enzymology, 316, 526–536.
Semple-Rowland, S. L., Lee, N. R., Van Hooser, J. P., Palczewski, K.,
& Baehr, W. (1998). A null mutation in the photoreceptor
guanylate cyclase gene causes the retinal degeneration chicken
phenotype. Proceedings of the National Academy of Sciences of the
United States of America, 95, 1271–1276.
Sieving, P. A., Chaudhry, P., Kondo, M., Provenzano, M., Wu, D.,
Carlson, T. J., Bush, R. A., & Thompson, D. A. (2001). Inhibition
of the visual cycle in vivo by 13-cis retinoic acid protects from light
damage and provides a mechanism for night blindness in isotre-
tinoin therapy. Proceedings of the National Academy of Sciences of
the United States of America, 98, 1835–1840.
Suber, M. L., Pittler, S. J., Qin, N., Wright, G. C., Holcombe, V., Lee,
R. H., Craft, C. M., Lolley, R. N., Baehr, W., & Hurwitz, R. L.
(1993). Irish setter dogs aﬀected with rod/cone dysplasia contain
a nonsense mutation in the rod cGMP phosphodiesterase beta
subunit gene. Proceedings of the National Academy of Sciences of
the United States of America, 90, 3968–3972.
Sun, H., & Nathans, J. (2001). ABCR, the ATP-binding cassette
transporter responsible for Stargardt macular dystrophy, is an
eﬃcient target of all-trans-retinal-mediated photooxidative damage
in vitro. Implications for retinal disease. Journal of Biological
Chemistry, 276, 11766–11774.
Travis, G. H., Brennan, M. B., Danielson, P. E., Kozak, C. A., &
Sutcliﬀe, J. G. (1989). Identiﬁcation of a photoreceptor-speciﬁc
mRNA encoded by the gene responsible for retinal degeneration
slow (rds). Nature, 338, 70–73.
Travis, G. H., Sutcliﬀe, J. G., & Bok, D. (1991). The retinal
degeneration slow (rds) gene product is a photoreceptor disc
membrane-associated glycoprotein. Neuron, 6, 61–70.
398 G.J. Chader / Vision Research 42 (2002) 393–399
Van Hooser, J. P., Aleman, T. S., He, Y. G., Cideciyan, A. V., Kuksa,
V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K.
(2000). Rapid restoration of visual pigment and function with oral
retinoid in a mouse model of childhood blindness [in process
citation]. Proceedings of the National Academy of Sciences of the
United States of America, 97, 8623–8628.
Van Nie, R., Ivanyi, D., & Demant, P. (1978). A new H-2-linked
mutation, rds, causing retinal degeneration in the mouse. Tissue
Antigens, 12, 106–108.
Wells, J., Wroblewski, J., Keen, J., Inglehearn, C., Jubb, C., Eckstein,
A., Jay, M., Arden, G., Bhattacharya, S., Fitzke, F., & Bird, A.
(1993). Mutations in the human retinal degeneration slow (RDS)
gene can cause either retinitis pigmentosa or macular dystrophy.
Nature Genetics, 3, 213–217.
Weng, J., Mata, N. L., Azarian, S. M., Tzekov, R. T., Birch, D. G., &
Travis, G. H. (1999). Insights into the function of Rim protein in
photoreceptors and etiology of Stargardt’s disease from the
phenotype in abcr knockout mice. Cell, 98, 13–23.
Wenzel, A., Grimm, C., Seeliger, M. W., Jaissle, G., Hafezi, F.,
Kretschmer, R., Zrenner, E., & Reme, C. E. (2001). Prevention of
photoreceptor apoptosis by activation of the glucocorticoid recep-
tor. Investigative Ophthalmology and Visual Science, 42, 1653–
1659.
Young, M. J., Ray, J., Whiteley, S. J., Klassen, H., & Gage, F. H.
(2000). Neuronal diﬀerentiation and morphological integration of
hippocampal progenitor cells transplanted to the retina of imma-
ture and mature dystrophic rats. Molecular and Cellular Neuro-
science, 16, 197–205.
G.J. Chader / Vision Research 42 (2002) 393–399 399
